Neurocrine Biosciences, Inc. (BIT:1NBIX)
Italy · Delayed Price · Currency is EUR 118.20
0.00 (0.00%)
Last updated: Oct 7, 2025, 9:00 AM CET
Neurocrine Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Cash & Equivalents | 264 | 233 | 251.1 | 262.9 | 340.8 | 187.1 | Upgrade |
Short-Term Investments | 711.6 | 843.1 | 780.5 | 726.4 | 370.5 | 613.9 | Upgrade |
Cash & Short-Term Investments | 975.6 | 1,076 | 1,032 | 989.3 | 711.3 | 801 | Upgrade |
Cash Growth | -6.09% | 4.31% | 4.28% | 39.08% | -11.20% | 19.46% | Upgrade |
Accounts Receivable | 595.7 | 479.1 | 439.3 | 350 | 185.5 | 157.1 | Upgrade |
Inventory | 56.9 | 57.4 | 38.3 | 35.1 | 30.5 | 28 | Upgrade |
Other Current Assets | 120.7 | 112.1 | 97.8 | 79.1 | 45.5 | 30.1 | Upgrade |
Total Current Assets | 1,749 | 1,725 | 1,607 | 1,454 | 972.8 | 1,016 | Upgrade |
Net Property, Plant & Equipment | 584 | 592 | 347.3 | 145.6 | 155.8 | 127.4 | Upgrade |
Other Intangible Assets | 37.2 | 36.5 | 35.5 | 37.2 | - | - | Upgrade |
Long-Term Investments | 961.3 | 864.3 | 849.4 | 401.5 | 624.4 | 265.3 | Upgrade |
Other Long-Term Assets | 558.4 | 501.2 | 412.2 | 330.9 | 319.5 | 325.8 | Upgrade |
Total Assets | 3,890 | 3,719 | 3,251 | 2,369 | 2,073 | 1,735 | Upgrade |
Accounts Payable | 489.5 | 461.6 | 448.8 | 347.6 | 225.8 | 168.7 | Upgrade |
Current Portion of Long-Term Debt | - | - | 170.1 | 169.4 | - | - | Upgrade |
Other Current Liabilities | 56.8 | 46.1 | 35.9 | 20.7 | 20 | 17.8 | Upgrade |
Total Current Liabilities | 546.3 | 507.7 | 654.8 | 537.7 | 245.8 | 186.5 | Upgrade |
Long-Term Debt | - | - | - | - | 335.1 | 317.9 | Upgrade |
Long-Term Leases | 439.1 | 455.1 | 258.3 | 93.5 | 105.3 | 94.4 | Upgrade |
Other Long-Term Liabilities | 210.1 | 166.2 | 106.3 | 29.7 | 12.3 | 9.7 | Upgrade |
Total Long-Term Liabilities | 649.2 | 621.3 | 364.6 | 123.2 | 452.7 | 422 | Upgrade |
Total Liabilities | 1,196 | 1,129 | 1,019 | 660.9 | 698.5 | 608.5 | Upgrade |
Preferred Stock | 0.1 | 0.1 | - | - | - | - | Upgrade |
Common Stock | 2,597 | 2,555 | 0.1 | 0.1 | 0.1 | 0.1 | Upgrade |
Additional Paid-in Capital | 12.5 | 5.8 | 2,382 | 2,122 | 2,011 | 1,850 | Upgrade |
Accumulated Other Comprehensive Income | 84.5 | 29.2 | 7 | -7.9 | -1.7 | 1.8 | Upgrade |
Retained Earnings | - | - | -157.1 | -406.8 | -635.8 | -725.4 | Upgrade |
Shareholders' Equity | 2,694 | 2,590 | 2,232 | 1,708 | 1,374 | 1,126 | Upgrade |
Total Liabilities & Equity | 3,890 | 3,719 | 3,251 | 2,369 | 2,073 | 1,735 | Upgrade |
Total Debt | 439.1 | 455.1 | 428.4 | 262.9 | 440.4 | 412.3 | Upgrade |
Net Cash (Debt) | 536.5 | 621 | 603.2 | 726.4 | 270.9 | 388.7 | Upgrade |
Net Cash Growth | -13.61% | 2.95% | -16.96% | 168.14% | -30.31% | 122.11% | Upgrade |
Net Cash Per Share | 5.23 | 5.99 | 5.97 | 7.34 | 2.77 | 3.97 | Upgrade |
Book Value | 2,694 | 2,590 | 2,232 | 1,708 | 1,374 | 1,126 | Upgrade |
Book Value Per Share | 26.25 | 24.97 | 22.10 | 17.27 | 14.03 | 11.52 | Upgrade |
Tangible Book Value | 2,657 | 2,553 | 2,197 | 1,671 | 1,374 | 1,126 | Upgrade |
Tangible Book Value Per Share | 25.89 | 24.62 | 21.75 | 16.89 | 14.03 | 11.52 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.